Tumor-infiltrating Lymphocytes As a Prognostic and Predictive Factor for Melanoma

Overview

Journal Expert Rev Mol Diagn

Specialty Molecular Biology

Date 2024 Feb 5

PMID 38314660

Authors

Gracia Maria Vargas

Neha Shafique

Xiaowei Xu

Giorgos Karakousis

Affiliations

Soon will be listed here.

Abstract

Introduction: Tumor-infiltrating lymphocytes (TILs) have been investigated as prognostic factors in melanoma. Recent advancements in assessing the tumor microenvironment in the setting of more widespread use of immune checkpoint blockade have reignited interest in identifying predictive biomarkers. This review examines the function and significance of TILs in cutaneous melanoma, evaluating their potential as prognostic and predictive markers.

Areas Covered: A literature search was conducted on papers covering tumor infiltrating lymphocytes in cutaneous melanoma available online in PubMed and Web of Science from inception to 1 December 2023, supplemented by citation searching. This article encompasses the assessment of TILs, the role of TILs in the immune microenvironment, TILs as a prognostic factor, TILs as a predictive factor for immunotherapy response, and clinical applications of TILs in the treatment of cutaneous melanoma.

Expert Opinion: Tumor-infiltrating lymphocytes play a heterogeneous role in cutaneous melanoma. While they have historically been associated with improved survival, their status as independent prognostic or predictive factors remains uncertain. Novel methods of TIL assessment, such as determination of TIL subtypes and molecular signaling, demonstrate potential for predicting therapeutic response. Further, while their clinical utility in risk-stratification in melanoma treatment shows promise, a lack of consensus data hinders standardized application.

Citing Articles

A Narrative Review of Prognostic Gene Signatures in Oral Squamous Cell Carcinoma Using LASSO Cox Regression.

Mohd Faizal N, Shai S, Savaliya B, Karen-Ng L, Kumari R, Kumar R Biomedicines. 2025; 13(1).

PMID: 39857718 PMC: 11759772. DOI: 10.3390/biomedicines13010134.

References

Duprat J, Brechtbulh E, Costa de Sa B, Enokihara M, Humberto Fregnani J, Landman G . Absence of Tumor-Infiltrating Lymphocyte Is a Reproducible Predictive Factor for Sentinel Lymph Node Metastasis: A Multicenter Database Study by the Brazilian Melanoma Group. PLoS One. 2016; 11(2):e0148160. PMC: 4747578. DOI: 10.1371/journal.pone.0148160. View

Robert L, Harview C, Emerson R, Wang X, Mok S, Homet B . Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes. Oncoimmunology. 2014; 3:e29244. PMC: 4108466. DOI: 10.4161/onci.29244. View

Clark Jr W, From L, Bernardino E, Mihm M . The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969; 29(3):705-27. View

Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J . A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med. 2011; 9:204. PMC: 3239318. DOI: 10.1186/1479-5876-9-204. View

Halse H, Colebatch A, Petrone P, Henderson M, Mills J, Snow H . Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma. Sci Rep. 2018; 8(1):11158. PMC: 6057961. DOI: 10.1038/s41598-018-28944-3. View

Shin D, Ribas A . The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?. Curr Opin Immunol. 2015; 33:23-35. DOI: 10.1016/j.coi.2015.01.006. View

Urso C . Are growth phases exclusive to cutaneous melanoma?. J Clin Pathol. 2004; 57(5):560. PMC: 1770294. DOI: 10.1136/jcp.2003.014852. View

Sarnaik A, Hamid O, Khushalani N, Lewis K, Medina T, Kluger H . Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. J Clin Oncol. 2021; 39(24):2656-2666. PMC: 8376325. DOI: 10.1200/JCO.21.00612. View

Fu Q, Chen N, Ge C, Li R, Li Z, Zeng B . Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis. Oncoimmunology. 2019; 8(7):1593806. PMC: 6527267. DOI: 10.1080/2162402X.2019.1593806. View

10.

Kruper L, Spitz F, Czerniecki B, Fraker D, Blackwood-Chirchir A, Ming M . Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma. Cancer. 2006; 107(10):2436-45. DOI: 10.1002/cncr.22295. View

11.

Tan W, Nerurkar S, Cai H, Ng H, Wu D, Wee Y . Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy. Cancer Commun (Lond). 2020; 40(4):135-153. PMC: 7170662. DOI: 10.1002/cac2.12023. View

12.

Hussaini H, Seo B, Rich A . Immunohistochemistry and Immunofluorescence. Methods Mol Biol. 2022; 2588:439-450. DOI: 10.1007/978-1-0716-2780-8_26. View

13.

Stahl P, Salmen F, Vickovic S, Lundmark A, Fernandez Navarro J, Magnusson J . Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. Science. 2016; 353(6294):78-82. DOI: 10.1126/science.aaf2403. View

14.

Parra E, Uraoka N, Jiang M, Cook P, Gibbons D, Forget M . Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues. Sci Rep. 2017; 7(1):13380. PMC: 5645415. DOI: 10.1038/s41598-017-13942-8. View

15.

Clark Jr W, Elder D, Guerry 4th D, Braitman L, Trock B, Schultz D . Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989; 81(24):1893-904. DOI: 10.1093/jnci/81.24.1893. View

16.

Riaz N, Havel J, Makarov V, Desrichard A, Urba W, Sims J . Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017; 171(4):934-949.e16. PMC: 5685550. DOI: 10.1016/j.cell.2017.09.028. View

17.

Osella-Abate S, Conti L, Annaratone L, Senetta R, Bertero L, Licciardello M . Phenotypic characterisation of immune cells associated with histological regression in cutaneous melanoma. Pathology. 2019; 51(5):487-493. DOI: 10.1016/j.pathol.2019.04.001. View

18.

Lee H, Pires da Silva I, Palendira U, Scolyer R, Long G, Wilmott J . Targeting NK Cells to Enhance Melanoma Response to Immunotherapies. Cancers (Basel). 2021; 13(6). PMC: 8002669. DOI: 10.3390/cancers13061363. View

19.

Yonick D, Ballo R, Kahn E, Dahiya M, Yao K, Godellas C . Predictors of positive sentinel lymph node in thin melanoma. Am J Surg. 2011; 201(3):324-7. DOI: 10.1016/j.amjsurg.2010.09.011. View

20.

Chatziioannou E, Rossner J, Aung T, Rimm D, Niessner H, Keim U . Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases. EBioMedicine. 2023; 93:104644. PMC: 10363450. DOI: 10.1016/j.ebiom.2023.104644. View